Home / Market News / $QNTM

$QNTM news and market catalysts

The 12 most recent market catalysts affecting $QNTM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

12 catalysts 4 high impact 7 bullish 1 bearish Technology
Nov 17, 2026 Corporate Catalyst Bullish Impact 85
Quanome Technologies Reports Fiscal First-Quarter Results
Quanome Technologies reported securing its first enterprise customer agreement for AI inference services, which includes a substantial $13.5 million prepayment. This event is highl…
Nov 8, 2026 Corporate Catalyst Bearish Impact 65
JPMorgan Adjusts Price Target for Quantinuum Inc.
JPMorgan's decision to lower Quantinuum Inc.'s price target from $97 to $80 signals a less favorable outlook for the quantum computing company. This adjustment, based on recent fin…
Oct 15, 2026 Corporate Catalyst Bullish Impact 75
Quantinuum shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.
The upgrade from Morgan Stanley, a prominent investment bank, from 'Equal-Weight' to 'Overweight' is a strong positive signal for Quantinuum. This indicates that Morgan Stanley ana…
Oct 6, 2026 Corporate Catalyst Bullish Impact 75
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
Quantum BioPharma (QNTM) has reached a critical milestone by advancing its progressive multiple sclerosis drug, Lucid-MS, into a Phase 2 clinical trial. The partnership with Thermo…
Oct 5, 2026 Corporate Catalyst Neutral Impact 55
Quanome Technologies To Purchase An Additional 32 GPU Server Units From Compal Electronics For ~$18.8M
Quanome Technologies is expanding its computing capabilities by acquiring 32 additional GPU server units from Compal Electronics for $18.8 million. This transaction is significant …
Sep 24, 2026 Corporate Catalyst Neutral Impact 55
Quantum BioPharma’s Licensee Unbuzzd Wellness Announces Appointment Of Michael Zapolin As CEO
Quantum BioPharma announced that its licensee, Unbuzzd Wellness, has appointed Michael Zapolin as CEO. This is a significant development for Unbuzzd, as Zapolin's mandate includes …
Sep 22, 2026 Corporate Catalyst Bullish Impact 75
Quanome Technologies shares are trading higher after the company announced it entered into a Purchase and Sale Agreement and related purchase order with Compal Electronics for the purchase of 32 GPU server units.
This headline represents a significant corporate catalyst for Quanome Technologies, indicating strong demand for its GPU server solutions, likely driven by the booming AI sector. T…
Sep 2, 2026 Corporate Catalyst Neutral Impact 55
Reported Earlier, Quantum BioPharma Plans To Leave Canadian Exchange While Keeping Nasdaq Listing
Quantum BioPharma is delisting its Class B shares from the Canadian Securities Exchange (CSE) while maintaining its Nasdaq listing. The company believes the trading volume on the C…
Aug 31, 2026 Corporate Catalyst Neutral Impact 65
Rodman & Renshaw Initiates Coverage On Quantum BioPharma with Buy Rating, Announces Price Target of $8
Rodman & Renshaw analyst Michael King has initiated coverage on Quantum BioPharma (QNTM) with a 'Buy' rating and an $8 price target. This is a significant event for QNTM as new ana…
Aug 11, 2026 Corporate Catalyst Bullish Impact 85
Quantum shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates.
This headline is a significant corporate catalyst, directly impacting Quantum's stock price positively due to better-than-expected financial performance and optimistic forward guid…
Aug 10, 2026 Corporate Catalyst Bullish Impact 85
Quantum shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates.
This headline is a strong positive catalyst for Quantum (QNTM). Better-than-expected financial results and optimistic forward guidance typically signal healthy business fundamental…
Aug 10, 2026 Corporate Catalyst Bullish Impact 85
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial
Quantum BioPharma (QNTM) announced FDA clearance for its Lucid-MS IND application, enabling the drug to enter Phase 2 clinical trials for multiple sclerosis. This is a crucial step…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.